The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Descripción completa

Detalles Bibliográficos
Autores principales: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://www.ncbi.nlm.nih.gov/pubmed/28367429
http://dx.doi.org/10.1155/2017/6468309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://www.ncbi.nlm.nih.gov/pubmed/28367429
http://dx.doi.org/10.1155/2017/6468309

Ejemplares similares